Breaking new grounds in diabetes treatment, Glenmark Pharmaceuticals Limited has introduced the first-ever triple-drug fixed-dose combination in India. Named Zita DM, this innovative formulation combines Teneligliptin, Dapagliflozin, and Metformin SR, providing a powerful daily solution for Type 2 diabetes management. According to official statements, this groundbreaking FDC promises enhanced glycemic control, and it’s a testament to Glenmark’s commitment to cutting-edge healthcare. Read more to understand new Zita DM
Zita DM: A Triple-Therapeutic Powerhouse
Glenmark Pharmaceuticals introduces Zita DM, a groundbreaking triple-fixed-dose combination (FDC) drug designed to elevate glycemic control in Type 2 diabetes patients. This potent fusion of Teneligliptin (20 mg), Dapagliflozin(10 mg) , and Metformin SR (1000 mg) marks a significant leap in diabetes care.
Targeting Glycated Haemoglobin (HBA1c) Levels Zita DM is tailored for adult patients with elevated HBA1c levels and co-existing conditions. It steps in where conventional metformin therapy falls short, providing a powerful tool to manage diabetes effectively.
Affordability Meets Effectiveness: Priced at Rs 14 Per Tablet At an affordable cost of Rs 14 per tablet, Zita DM promises a 30% reduction in daily therapy expenses. This remarkable affordability empowers a wider demographic of patients to access this cutting-edge solution for improved glycemic regulation.
Alok Malik’s Vision: Enhanced Glycemic Control and Beyond
Alok Malik, President & Business Head at Glenmark Pharma, envisions Zita DM as a novel and accessible anti-diabetic drug. Beyond glycemic control, it aims to reduce major renal and cardiac adverse events, offering comprehensive care for patients with high HBA1c and co-morbidities.
Glenmark’s Zita Portfolio: Nurturing 1.75 Million Lives Annually
Glenmark’s Zita portfolio has been a stalwart in serving 1.75 million Type 2 diabetic patients annually in India. With the introduction of Zita DM, the company expands its commitment to enhancing the lives of those grappling with diabetes and related conditions.
Market Insights: Reshaping Diabetes Pharmaceuticals Landscape
a. IQVIA Sales Data: A Glimpse into the Indian Market For the 12 months ending August 2023, the Indian market for oral anti-diabetic drugs stands at an estimated Rs 12,522 crores, with a 6.5% year-on-year growth. This data underscores the significance of Glenmark’s innovative approach.
b. Anticipating the Future with Expired Drug Patents
With patents expiring on key diabetes drugs, including Sitagliptin and Vildagliptin, the market is poised for a shift towards more accessible treatment options. Zita DM’s arrival aligns perfectly with this evolving landscape.
Unpacking Zita DM: Components and Dosage Zita DM combines the strengths of Teneligliptin, Dapagliflozin, and Metformin SR in a fixed dose. Together, they enhance insulin sensitivity, regulate blood sugar levels, and empower diabetes control. This single daily pill simplifies adherence, ensuring seamless treatment.
Beyond Glycemic Control: Zita DM’s Promise of Reduced Adverse Events Zita DM not only focuses on glycemic regulation but also aims to minimize major renal and cardiac adverse events. This dual benefit sets a new standard in comprehensive diabetes care.
Market Impact: Affordable and Effective Diabetes Management Empowering Accessibility and Affordability Priced at Rs 14 per tablet, Zita DM breaks barriers in making advanced diabetes care accessible to a wider demographic. Its affordability factor is poised to positively impact the diabetes treatment landscape.
A Potential Catalyst for Positive Health Outcomes
Zita DM’s introduction marks a pivotal moment in diabetes management, promising improved glycemic control and reduced adverse events. It stands as a beacon of hope for patients seeking an effective and affordable solution.
The Glenmark Promise: Pioneering Healthcare Innovation
As a pioneer in diabetes care, Glenmark Pharmaceuticals reaffirms its commitment to innovation and patient-centric solutions. With Zita DM, they’ve raised the bar for diabetes treatment, offering a transformative option for millions of patients.
As Zita DM emerges as a beacon of hope in Type 2 diabetes care, one can’t help but wonder: What could the future hold for this groundbreaking combination? With its unique blend of Teneligliptin, Dapagliflozin, and Metformin SR, the potential for transformative advancements in diabetes management is palpable. Let’s watch as Zita DM paves the way for a brighter future in healthcare.
